Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

OpenAI is joining forces with two European companies to set up a data center in Norway, the ChatGPT maker's first project of this kind on the continent as it seeks to expand artificial-intelligence ...

Bristol Myers Squibb reported unexpectedly strong second-quarter results, driven by legacy products like Eliquis, despite ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

By Michael Erman and Bhanvi Satija (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on ...

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Live Updates Live Coverage Updates appear automatically as they are published. MassterCard Charges Ahead 10:00 am In further ...

AbbVie's beat Wall Street's estimates for its top- and bottom-lines in the second quarter, boosted by sales of Skyrizi and Rinvoq. S&P Global said second-quarter profit rose due to "resilience in the ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...